Biologics and pregnancy: a clinician’s guide to the management of IBD in pregnant women

References

• Johnston RD, Logan RFA. What is the peak age for onset of IBD? Inflamm Bowel Dis. 2008Oct;14:S4–S5.
   PubMed Web of Science ®Google Scholar
• Shivashankar R, Tremaine WJ, Harmsen WS, et al. Incidence and prevalence of crohn’s disease and ulcerative colitis in olmsted county, minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15:857–863.
   PubMed Web of Science ®Google Scholar
• Mathews TJ, Hamilton BE. Mean Age of mothers is on the rise: United States, 2000–2014 key findings data from the national vital statistics system. 2000.
   Google Scholar
• Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. World J. Gastroenterol. 2011;17:2696.
   PubMed Web of Science ®Google Scholar
• Friedman S, Nielsen J, Nøhr EA, et al. Comparison of time to pregnancy in women with and without inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020 June;18(7):1537–1544.e1.
   PubMed Web of Science ®Google Scholar
• Mountifield R, Bampton P, Prosser R, et al. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm. Bowel Dis. 2009;15:720–725.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the american gastroenterological association ibd parenthood project working group. Am. J. Obstet. Gynecol. 2019;220(4):308–323.
   PubMed Web of Science ®Google Scholar
• Nørgård B, Hundborg HH, Jacobsen BA, et al. Disease activity in pregnant women with crohn’s disease and birth outcomes: a regional danish cohort study. Am J Gastroenterol. 2007 Sept;102(9):1947–1954.
   PubMed Web of Science ®Google Scholar
• Romero R, Gotsch F, Pineles B, et al. Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr. Rev. 2007 Dec;65(SUPPL.3):194–202.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Boudreau H, Harris ML, et al. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2009 Mar;7(3):329–334.
   PubMed Web of Science ®Google Scholar
• de Lima A, Zelinkova Z, Mulders AGMGJ, et al. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin. Gastroenterol. Hepatol. 2016;14:1285–1292.e1.
   PubMed Web of Science ®Google Scholar
• Wu G, Bazer FW, Cudd TA, et al. Maternal nutrition and fetal development. J Nutr. 2004;134(9):2169–2172. American Institute of Nutrition.
   PubMed Web of Science ®Google Scholar
• Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007 June;56(6):830–837.
   PubMed Web of Science ®Google Scholar
• Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003–2006. Aliment. Pharmacol. Ther. 2011 Oct;34(7):724–734.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in ulcerative colitis. Scand J Gastroenterol. 1983 Sept;18(6):735–742.
   PubMed Web of Science ®Google Scholar
• Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology. 1990 Oct;99(4):987–994.
   PubMed Web of Science ®Google Scholar
• Afzali A. Inflammatory bowel disease during pregnancy. Curr Opin Gastroenterol. 2019 July;35(4):281–287.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Seow CH, Maxwell C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016 Mar;150(3):734–757.e1.
   PubMed Web of Science ®Google Scholar
• Bush M, Patel S, Lapinski R, et al. Perinatal outcomes in inflammatory bowel disease. J Matern Neonatal Med. 2004 Apr;15(4):237–241.
   PubMedGoogle Scholar
• Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis. 2008;14:1736–1750.
   Web of Science ®Google Scholar
• Khosla R, Willoughby CP, Jewell DP. Crohn’s disease and pregnancy. Gut. 1984 Jan;25(1):52–56.
   PubMed Web of Science ®Google Scholar
• Stephansson O, Larsson H, Pedersen L, et al. Crohn’s disease is a risk factor for preterm birth. Clin. Gastroenterol. Hepatol. 2010 June;8(6):509–515.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Sandborn WJ, Li D, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007 Oct;133(4):1106–1112.
   PubMed Web of Science ®Google Scholar
• Dominitz JA, Young JCC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol. 2002 Mar;97(3):641–648.
   PubMed Web of Science ®Google Scholar
• Molnár T, Farkas K, Nagy F, et al. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case–control study. Scand. J. Gastroenterol. 2010 Nov;45(11):1302–1306.
   PubMed Web of Science ®Google Scholar
• Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm. Bowel Dis. 2011 Mar;17(3):795–801.
   PubMed Web of Science ®Google Scholar
• Ban L, Tata LJ, Fiaschi L, et al. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology. 2014;146(1):76–84.
   PubMed Web of Science ®Google Scholar
• Leung KK, Tandon P, Govardhanam V, et al. The risk of adverse neonatal outcomes with maternal inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. May 2020. DOI:10.1093/ibd/izaa122
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Long MD, Kane SV, et al. pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2020 Nov. DOI:10.1053/j.gastro.2020.11.038
   Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2013 Mar;11(3):286–292.
   PubMed Web of Science ®Google Scholar
• P683 Infliximab, adalimumab and vedolizumab levels are not altered by pregnancy progression in IBD patients and neonatal vedolizumab levels are lower than in mothers: results from the PICCOLO study. [ cited 2020 Nov 4]. Available from: https://ecco-ibd.eu/publications/congress-abstracts/item/p683-infliximab-adalimumab-and-vedolizumab-levels-are-not-altered-by-pregnancy-progression-in-ibd-patients-and-neonatal-vedolizumab-levels-are-lower-than-in-mothers-results-from-the-piccolo-study.html
   Google Scholar
• Flanagan E, Gibson PR, Wright EK, et al. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020;52(10). DOI:10.1111/apt.16102
   Web of Science ®Google Scholar
• Seow CH, Leung Y, Vande Casteele N, et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2017 May;45(10):1329–1338.
   PubMed Web of Science ®Google Scholar
• Grišić AM, Dorn-Rasmussen M, Ungar B, et al. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. United Eur. Gastroenterol. J. 2020;205064062096461. DOI:10.1177/2050640620964619
   PubMed Web of Science ®Google Scholar
• Porter C, Armstrong-Fisher S, Kopotsha T, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J. Reprod. Immunol. 2016Aug;116:7–12.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Verreth A, Lobaton T, et al. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: results from the multicenter european teddy study. Am. J. Gastroenterol. 2018 Mar;113(3):396–403.
   PubMed Web of Science ®Google Scholar
• Luu M, Benzenine E, Doret M, et al. Continuous anti-TNFα use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the french national health insurance database (EVASION). Am. J. Gastroenterol. 2018;113(11):1669–1677.
   PubMed Web of Science ®Google Scholar
• Truta B, Leeds IL, Canner JK, et al. Early discontinuation of infliximab in pregnant women with inflammatory bowel disease. Inflammatory Bowel Diseases. 2020 June;26(7):1110–1117.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Gubatan JM, Juhl CB, et al. Journal pre-proof biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020. DOI:10.1016/j.cgh.2020.09.021
   Web of Science ®Google Scholar
• Shihab Z, Yeomans ND, De Cruz P. Anti-tumour necrosis factor α therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis. J Crohn’s Colitis. 2016;10(8):979–988. Oxford University Press.
   Google Scholar
• Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104(1):228–233.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Gisbert JP. Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. Curr Pharm Biotechnol. 2012 Apr;12(5):765–773.
   Web of Science ®Google Scholar
• Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016 July;151(1):110–119.
   PubMed Web of Science ®Google Scholar
• McConnell RA, Mahadevan U. Use of immunomodulators and biologics before, during, and after pregnancy. Inflamm Bowel Dis. 2016 Jan 1;22(1):213–223. Lippincott Williams and Wilkins.
   PubMed Web of Science ®Google Scholar
• De Lima A, Zelinkova Z, Van Der Ent C, et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016 Aug;65(8):1261–1268.
   PubMed Web of Science ®Google Scholar
• Narula N, Al-Dabbagh R, Dhillon A, et al. Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1862–1869.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Martin CF, Sandler RS, et al. 865 PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012 May;142(5):S–149.
   Web of Science ®Google Scholar
• Roy A, Chambers CD, Martin C, et al. Exposure to biologic therapy and childhood development among offspring of women with inflammatory bowel disease: results from the piano registry. Gastroenterology. 2017 Apr;152(5):S85–S86.
   Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016 Jan 7;7(1):e135. Nature Publishing Group.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin. Gastroenterol. Hepatol. 2004 July;2(7):542–553.
   PubMed Web of Science ®Google Scholar
• Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol. 2004 Dec;99(12):2385–2392.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am. J. Gastroenterol. 2012 Sept;107(9):1409–1422.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm. Bowel Dis. 2011 Sept;17(9):1846–1854.
   PubMed Web of Science ®Google Scholar
• Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2014;40(4):363–373.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Mahadevan U, et al. Pregnancy outcomes reported during the 13-year TREAT registry: a descriptive report. Am. J. Gastroenterol. 2018 Nov;113(11):1678–1688.
   PubMed Web of Science ®Google Scholar
• Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment. Pharmacol. Ther. 2020 Jan;51(1):129–138.
   PubMed Web of Science ®Google Scholar
• Terjung B, Schmelz R, Ehehalt R, et al. Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review. Therap. Adv. Gastroenterol. 2020;13. DOI:10.1177/1756284820952592
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2017;45:941–950.
   Web of Science ®Google Scholar
• Chambers C, Adams J, Johnson D, et al. 717 the vedolizumab pregnancy exposure registry: an OTIS pregnancy study update. Am J Gastroenterol. 2019 Oct;114(1):S421–S422.
   Web of Science ®Google Scholar
• Flanagan E, Gibson PR, Begun J, et al. Letter: vedolizumab drug concentrations in neonates following intrauterine exposure. Aliment Pharmacol Ther. 2018 Dec 1;48(11–12):1328–1330. Blackwell Publishing Ltd.
   PubMed Web of Science ®Google Scholar
• Wils P, Seksik P, Stefanescu C, et al. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Aliment Pharmacol Ther. 2020. DOI:10.1111/APT.16192
   Web of Science ®Google Scholar
• Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 2018 Sept;70(9):1399–1407.
   PubMed Web of Science ®Google Scholar
• Venturin C, Nancey S, Danion P, et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterology. 2017 June;17(1). DOI:10.1186/s12876-017-0633-6
   PubMed Web of Science ®Google Scholar
• Hoentjen F, Haarhuis BJT, Drenth JPH, et al. Elective switching from infliximab to adalimumab in stable crohn’s disease. Inflamm Bowel Dis. 2013 Mar;19(4):761–766.
   PubMed Web of Science ®Google Scholar
• Drugs and Lactation Database (LactMed). 2006 [cited 2020 Nov 5]. [Online]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/
   Google Scholar
• Matro R, Martin CF, Wolf D, et al. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018 Sept;155(3):696–704.
   PubMed Web of Science ®Google Scholar
• Berends SE, Strik AS, Löwenberg M, et al. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis. Clin Pharmacokinet. 2019 Jan 17;58(1):15–37. Springer International Publishing.
   PubMed Web of Science ®Google Scholar
• Julsgaard M, Kjeldsen J, Bibby BM, et al. Vedolizumab concentrations in the breast milk of nursing mothers with inflammatory bowel disease. Gastroenterology. 2018 Feb 1;154(3):752–754.e1. W.B. Saunders.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017 Nov;76(11):1890–1896.
   PubMed Web of Science ®Google Scholar
• Johnsson A, Avlund S, Grosen A, et al. Chicken pox infection in a three months old infant exposed in utero to Adalimumab. J Crohn’s Colitis. 2013 Apr 1;7(3). J Crohns Colitis. DOI: 10.1016/j.crohns.2012.07.020
   Google Scholar
• Cheent K, Nolan J, Shariq S, et al. Case Report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s Disease. J Crohn’s Colitis. 2010 Nov;4(5):603–605.
   Google Scholar
• Duricova D, Dvorakova E, Hradsky O, et al. Safety of anti-Tnf-Alpha therapy during pregnancy on long-Term outcome of exposed children: a controlled, multicenter observation. Inflamm Bowel Dis. 2019 Mar;25(4):789–796.
   PubMed Web of Science ®Google Scholar
• Gubatan J, Nielsen OH, Levitte S, et al. Biologics during pregnancy in women with inflammatory bowel disease and risk of infantile infections. Am J Gastroenterol. 2020;Publish Ah. DOI:10.14309/ajg.0000000000000910
   Web of Science ®Google Scholar
• Bortlik M, Duricova D, Machkova N, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm. Bowel Dis. 2014;20(3):495–501.
   PubMed Web of Science ®Google Scholar
• Beaulieu DB, Ananthakrishnan AN, Martin C, et al. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018 Jan;16(1):99–105.
   PubMed Web of Science ®Google Scholar
• Lim J, Hammami MB, Mahadevan U. Infliximab use in a child with ulcerative colitis and prior in utero exposure to infliximab. Gastroenterology. 2020 May;158(6):1834–1835.
   PubMed Web of Science ®Google Scholar